logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Innovative drug concept continues to be strong, Shu Tai Shen's 20CM hits limit up.

date
21/05/2025
Shutai Shen's 20cm limit up, previously Three Life National Health had 3 consecutive boards, followed by Sai Sheng Pharmaceutical, Haichuang Pharmaceutical, Haichen Pharmaceutical, Nosige, Junshi Biology, etc.
Latest
1 m ago
Wen Yuan Knowledge, a U.S. stock before the market rose by more than 3.3%, and upgraded its cooperation with Tencent Cloud.
1 m ago
Venustech's pre-market surge in US stocks exceeded 3.3%, advancing further through cooperation with Tencent Cloud.
2 m ago
British media: The United States has closed the Palestinian Affairs office.
3 m ago
Tianjin Branch of the People's Bank of China: Tianjin Pharmaceutical, Bohai Chemical, and Bohai Bank are expected to issue a total amount of 5.55 billion yuan.
4 m ago
Runto Group (002923.SZ): The drug registration certificate for the combination of olmesartan medoxomil and amlodipine has been obtained.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.